Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Subscribe To Our Newsletter & Stay Updated
